Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
Abstract Background/Objective There are limited real-world studies assessing semaglutide
weight loss and associated comorbidity and metabolic outcomes over periods≥ 6 months …
weight loss and associated comorbidity and metabolic outcomes over periods≥ 6 months …
Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study.
W Ghusn, S Fansa, D Anazco, E Tama… - … Journal of Obesity …, 2024 - europepmc.org
Results We included 304 patients (73% female, 93% White, mean age 48.8 [12.4] years, BMI
40.9 [9.6] kg/m 2) in the analysis. Patients achieved a TBWL of 13.4 (8.0)% at 12 months (p< …
40.9 [9.6] kg/m 2) in the analysis. Patients achieved a TBWL of 13.4 (8.0)% at 12 months (p< …
Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
W Ghusn, S Fansa, D Anazco… - … journal of obesity …, 2024 - pubmed.ncbi.nlm.nih.gov
Background/objective There are limited real-world studies assessing semaglutide weight
loss and associated comorbidity and metabolic outcomes over periods≥ 6 months. We aim …
loss and associated comorbidity and metabolic outcomes over periods≥ 6 months. We aim …
Weight loss and cardiovascular disease risk outcomes of semaglutide: a one-year multicentered study
W Ghusn, S Fansa, D Anazco… - … Journal of Obesity, 2024 - mayoclinic.elsevierpure.com
Background/Objective: There are limited real-world studies assessing semaglutide weight
loss and associated comorbidity and metabolic outcomes over periods≥ 6 months. We aim …
loss and associated comorbidity and metabolic outcomes over periods≥ 6 months. We aim …